Vandetanib
Sign in to save this workspacePrimary targets: KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
95.74
Gini
0.723
CATDS
0.016
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Vandetanib. Strongest target: EGFR at 99.3% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 99.3% | 0.7% |
| 2 | LCK | 98.9% | 1.1% |
| 3 | RET | 98.6% | 1.4% |
| 4 | DDR2 | 98.5% | 1.5% |
| 5 | DDR1 | 98.5% | 1.5% |
| 6 | LYN | 98.0% | 2.0% |
| 7 | EPHA6 | 97.3% | 2.7% |
| 8 | ABL1 | 95.7% | 4.3% |
| 9 | BRK | 95.3% | 4.7% |
| 10 | YES_YES1 | 95.2% | 4.8% |
| 11 | FLT4_VEGFR3 | 94.8% | 5.2% |
| 12 | KDR_VEGFR2 | 94.5% | 5.5% |
| 13 | PEAK1 | 94.4% | 5.6% |
| 14 | C_SRC | 94.2% | 5.8% |
| 15 | LOK_STK10 | 93.8% | 6.2% |
| 16 | BLK | 92.8% | 7.2% |
| 17 | FGFR2 | 90.8% | 9.2% |
| 18 | ABL2_ARG | 89.0% | 11.0% |
| 19 | FLT1_VEGFR1 | 88.6% | 11.4% |
| 20 | EPHB1 | 88.1% | 11.9% |
Selectivity landscape
Where Vandetanib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Vandetanib.
Atlas insights for Vandetanib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2493.47 | |
| ALLOGRAFT_REJECTION | 8873.12 | |
| ANDROGEN_RESPONSE | 1597.35 | |
| ANGIOGENESIS | 1823.91 | |
| APICAL_JUNCTION | 10177.71 | |
| APICAL_SURFACE | 1052.28 | |
| APOPTOSIS | 6909.58 | |
| BILE_ACID_METABOLISM | 1002.99 | |
| CHOLESTEROL_HOMEOSTASIS | 1715.36 | |
| COAGULATION | 1141.26 | |
| COMPLEMENT | 5706.60 | |
| DNA_REPAIR | 1757.27 | |
| E2F_TARGETS | 3382.48 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1696.15 | |
| ESTROGEN_RESPONSE_EARLY | 2507.71 | |
| ESTROGEN_RESPONSE_LATE | 2411.36 | |
| FATTY_ACID_METABOLISM | 914.45 | |
| G2M_CHECKPOINT | 3573.10 | |
| GLYCOLYSIS | 2638.70 | |
| HEDGEHOG_SIGNALING | 1067.26 | |
| HEME_METABOLISM | 1858.67 | |
| HYPOXIA | 3955.20 | |
| IL2_STAT5_SIGNALING | 2922.59 | |
| IL6_JAK_STAT3_SIGNALING | 4665.89 | |
| INFLAMMATORY_RESPONSE | 4660.88 | |
| INTERFERON_ALPHA_RESPONSE | 884.68 | |
| INTERFERON_GAMMA_RESPONSE | 5672.30 | |
| KRAS_SIGNALING_DN | 896.47 | |
| KRAS_SIGNALING_UP | 3694.69 | |
| MITOTIC_SPINDLE | 6469.03 | |
| MTORC1_SIGNALING | 3622.70 | |
| MYC_TARGETS_V1 | 2790.57 | |
| MYC_TARGETS_V2 | 520.17 | |
| MYOGENESIS | 2813.46 | |
| NOTCH_SIGNALING | 219.73 | |
| OXIDATIVE_PHOSPHORYLATION | 1632.85 | |
| P53_PATHWAY | 3476.87 | |
| PANCREAS_BETA_CELLS | 163.24 | |
| PEROXISOME | 1110.40 | |
| PI3K_AKT_MTOR_SIGNALING | 8576.33 | |
| PROTEIN_SECRETION | 2090.64 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 587.92 | |
| SPERMATOGENESIS | 1035.15 | |
| TGF_BETA_SIGNALING | 1705.05 | |
| TNFA_SIGNALING_VIA_NFKB | 3649.18 | |
| UNFOLDED_PROTEIN_RESPONSE | 998.40 | |
| UV_RESPONSE_DN | 4648.74 | |
| UV_RESPONSE_UP | 3465.38 | |
| WNT_BETA_CATENIN_SIGNALING | 1840.01 | |
| XENOBIOTIC_METABOLISM | 2182.16 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.828 |
| EPT0291 | EPN | 0.818 |
| SRR10899984 | — | 0.812 |
| aMVAC.P_005_TURBT_S223 | — | 0.808 |
| SRR12202498 | — | 0.801 |
Annotations
Sign in to read and post annotations.
Loading…